Weigang Guo

424 total citations
24 papers, 279 citations indexed

About

Weigang Guo is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Weigang Guo has authored 24 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Surgery and 8 papers in Molecular Biology. Recurrent topics in Weigang Guo's work include Lung Cancer Treatments and Mutations (7 papers), Esophageal Cancer Research and Treatment (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Weigang Guo is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Esophageal Cancer Research and Treatment (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Weigang Guo collaborates with scholars based in China, Ireland and Taiwan. Weigang Guo's co-authors include Junjie Xi, Chunlai Lu, Cheng Zhan, Yu Shi, Di Ge, Jianyong Ding, Qun Wang, Yuan Ji, Fei Shan and Yongxing Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Science Advances and Critical Care Medicine.

In The Last Decade

Weigang Guo

23 papers receiving 275 citations

Peers

Weigang Guo

PRM

ONCOL

RHEUM

Nadia Ben Lagha France

Aiko Kurisaki‐Arakawa Japan

Ka Su China

Hirochika Matsubara Japan

L. Ciuffreda Italy

Cristina Iosif Romania

Rong-Liang Shi China

Samantha Brownhill United Kingdom

Terrence A. Day United States

Nadia Ben Lagha France

Weigang Guo

80 ×0.8

PRM

119 ×1.2

36 ×0.5

ONCOL

54 ×0.8

28 ×0.6

RHEUM

Citations per year, relative to Weigang Guo Weigang Guo (= 1×) peers Nadia Ben Lagha

Countries citing papers authored by Weigang Guo

Since Specialization

Citations

This map shows the geographic impact of Weigang Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weigang Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weigang Guo more than expected).

Fields of papers citing papers by Weigang Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weigang Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weigang Guo. The network helps show where Weigang Guo may publish in the future.

Co-authorship network of co-authors of Weigang Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Weigang Guo. A scholar is included among the top collaborators of Weigang Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weigang Guo. Weigang Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Hongxia, Jiacheng Yin, Yuansheng Zheng, et al.. (2025). NDRG1‐Driven Lactate Accumulation Promotes Lung Adenocarcinoma Progression Through the Induction of an Immunosuppressive Microenvironment. Advanced Science. 12(33). e01238–e01238. 4 indexed citations

Fan, Xiaofei, Lin Cheng, Zongwei Chen, et al.. (2025). Metabolism-driven posttranslational modifications and immune regulation: Emerging targets for immunotherapy. Science Advances. 11(37). eadx6489–eadx6489. 1 indexed citations

Liang, Jiaqi, Yunyi Bian, Guangyao Shan, et al.. (2025). KLF13 promotes ferroptosis and chemosensitivity in lung adenocarcinoma. BMC Biology. 23(1). 178–178. 1 indexed citations

Liang, Jiaqi, et al.. (2024). miR‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. Thoracic Cancer. 15(30). 2206–2216. 3 indexed citations

Liu, Jun, Min Li, Xiaolin Wang, et al.. (2024). The associations between dysregulation of human blood metabolites and lung cancer risk: evidence from genetic data. BMC Cancer. 24(1). 854–854. 4 indexed citations

Shan, Guangyao, Jiaqi Liang, Xing Jin, et al.. (2024). Prognostic modeling and Emerging therapeutic targets Unveiled through single-cell sequencing in esophageal squamous Cell carcinoma. Heliyon. 10(19). e38078–e38078.

Liang, Jiaqi, et al.. (2023). Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer. Thoracic Cancer. 14(33). 3247–3258. 2 indexed citations

Chen, Zhencong, Yiwei Huang, Zhengyang Hu, et al.. (2021). Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. Oncogenesis. 10(10). 71–71. 30 indexed citations

Xi, Junjie, Zhengyang Hu, Jiaqi Liang, et al.. (2020). Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I–IIIA non-small cell lung cancer: a propensity-matched analysis. Journal of Thoracic Disease. 12(6). 3043–3056. 8 indexed citations

10.

Xi, Junjie, Mengnan Zhao, Yuansheng Zheng, et al.. (2020). Development and validation of a nomogram for predicting the overall survival of patients with lung large cell neuroendocrine carcinoma. Translational Cancer Research. 9(8). 4943–4957. 6 indexed citations

11.

Liang, Jiaqi, Qihai Sui, Yuansheng Zheng, et al.. (2020). A nomogram to predict prognosis of patients with lung adenosquamous carcinoma: a population-based study. Journal of Thoracic Disease. 12(5). 2288–2303. 6 indexed citations

12.

Yang, Xiaodong, Yu Shi, Ming Li, et al.. (2019). Identification and validation of an immune cell infiltrating score predicting survival in patients with lung adenocarcinoma. Journal of Translational Medicine. 17(1). 217–217. 37 indexed citations

13.

Yang, Yong, Cheng Zhan, Yiwei Huang, et al.. (2019). Benefits of surgery in the multimodality treatment of stage IIB-IIIC small cell lung cancer. Journal of Cancer. 10(22). 5404–5412. 13 indexed citations

14.

Huang, Yan, Weigang Guo, Shiming Shi, & Jian He. (2016). Evaluation of the 7th edition of the UICC-AJCC tumor, node, metastasis classification for esophageal cancer in a Chinese cohort. Journal of Thoracic Disease. 8(7). 1672–1680. 10 indexed citations

15.

Guo, Weigang, Yongxing Zhang, Yi Zhang, et al.. (2015). Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. International Journal of Molecular Medicine. 36(6). 1720–1726. 40 indexed citations

16.

Liu, Jianjun, et al.. (2014). Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine.. PubMed. 26(2). 88–94. 9 indexed citations

17.

Guo, Weigang, Q. Wang, Lin Xu, et al.. (2011). Diazoxide Decreases Ischemia-Reperfusion Injury in a Rat Model of Lung Transplantation. Transplantation Proceedings. 43(7). 2510–2516. 7 indexed citations

18.

Lu, Chunlai, Weigang Guo, Jianyong Ding, & Di Ge. (2008). Clinical and pathological analysis of solitary fibrous tumor of the pleura. 24(2). 91–94. 1 indexed citations

19.

Guo, Weigang, et al.. (2008). Preventive effects of curcumin and dexamethasone on lung transplantation-associated lung injury in rats. Critical Care Medicine. 36(4). 1205–1213. 30 indexed citations

20.

Ding, Jian‐Yong, Di Ge, Weigang Guo, & Chunlai Lu. (2008). Diazoxide-Mediated Growth Inhibition in Human Lung Cancer Cells via Downregulation of β-Catenin-Mediated Cyclin D1 Transcription. Lung. 187(1). 61–67. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact